Platelet-Rich Plasma in Musculoskeletal Degeneration: Focus on Rotator Cuff Tendinopathy and Hip Osteoarthritis

Rotator cuff tendinopathy and hip osteoarthritis (OA) represent two common, yet challenging musculoskeletal conditions. Despite distinct anatomical locations, both share degenerative pathophysiology and are associated with pain, disability, and progressive loss of function. Traditional treatments offer symptom relief but often fail to reverse tissue degeneration. The emergence of platelet-rich plasma (PRP) as a biologically active, regenerative therapy presents an evidence-supported alternative for these conditions. This article explores the clinical utility of PRP in rotator cuff tendinopathy and hip OA, focusing on mechanistic rationale, current data, and implementation strategies for physicians.

PRP Mechanisms in Tendon and Joint Degeneration

PRP is prepared from autologous whole blood and contains high concentrations of platelets, which release biologically active growth factors, including:

• Platelet-derived growth factor (PDGF)
• Transforming growth factor-beta (TGF-β1)
• Vascular endothelial growth factor (VEGF)
• Insulin-like growth factor-1 (IGF-1)

These growth factors promote angiogenesis, matrix synthesis, tenocyte proliferation, and modulate inflammation. In tendinopathy, PRP supports tendon matrix remodeling and cellular regeneration. In osteoarthritis, PRP may modulate synovial inflammation, enhance cartilage anabolism, and improve joint lubrication through hyaluronic acid stimulation.

PRP for Rotator Cuff Tendinopathy

Clinical Context

Rotator cuff tendinopathy involves chronic degeneration of one or more rotator cuff tendons, most commonly the supraspinatus. It presents with shoulder pain, night discomfort, and limited overhead motion. In partial-thickness tears or tendinosis, PRP is increasingly used to avoid progression and potential surgery.

Evidence Summary

• Kesikburun et al. (2013): PRP improved shoulder function and reduced pain more than placebo at 12 weeks.
• Rha et al. (2013): PRP showed greater improvement than dry needling in ultrasonographic tendon healing.
• Scarpone et al. (2020): Double-blind RCT showed functional gains and structural improvement on MRI in degenerative tendinopathy.

Injection Technique and Protocol

• PRP Type: Leukocyte-rich PRP (LR-PRP) commonly used
• Guidance: Ultrasound-guided injection into the degenerated tendon area
• Dosage: 1–2 injections spaced 2 weeks apart
• Rehabilitation: Sling for 48–72 hours; followed by progressive passive and active rehab

PRP for Hip Osteoarthritis

Clinical Context

Hip OA is a progressive disease involving cartilage loss, subchondral bone changes, and synovial inflammation. It leads to pain, stiffness, and functional limitation. In early-to-moderate OA (Kellgren-Lawrence grade 1–3), PRP has shown potential for delaying total hip replacement.

Evidence Summary

• Dallari et al. (2016): PRP provided superior results in pain and WOMAC function scores vs hyaluronic acid at 6 and 12 months.
• Raeissadat et al. (2019): Double PRP injections reduced pain and improved function in mild-to-moderate hip OA.
• Di Sante et al. (2021): PRP reduced NSAID dependence in hip OA compared to physical therapy alone.

Injection Technique and Protocol

• PRP Type: Leukocyte-poor PRP (LP-PRP) preferred to reduce inflammatory flare
• Guidance: Ultrasound or fluoroscopic intra-articular injection
• Dosage: 2–3 injections at 2–3 week intervals
• Post-injection Care: Weight-bearing as tolerated; avoid strenuous activity for 48–72 hours

Comparative Considerations

PRP application varies based on the target tissue and underlying pathology. Careful selection of PRP type and imaging-guided injection are essential to clinical success.

Limitations and Safety

PRP is generally well-tolerated with minimal risk of infection or adverse reactions due to its autologous nature. Potential drawbacks include:

• Post-injection discomfort
• Lack of standardized preparation protocols
• Variability in platelet concentration and leukocyte content

Contraindications:

• Coagulopathy or anticoagulant therapy
• Active infection
• Advanced joint degeneration (Kellgren-Lawrence grade 4)

Conclusion

PRP therapy represents an evolving and biologically rational approach to managing both rotator cuff tendinopathy and hip osteoarthritis. For physicians, PRP offers a minimally invasive option that may delay surgical intervention while improving pain and function. As with all orthobiologics, careful patient selection, standardized technique, and integration with rehabilitation are crucial for success.

References

1. Kesikburun S, et al. (2013). Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy. Am J Sports Med, 41(11):2609–2616.
2. Rha DW, et al. (2013). Comparing PRP and dry needling in rotator cuff disease. Clin Rehabil, 27(2):113–122.
3. Scarpone M, et al. (2020). Efficacy of PRP in chronic rotator cuff tendinopathy. Arch Phys Med Rehabil, 101(2):202–209.
4. Dallari D, et al. (2016). PRP vs HA in hip osteoarthritis: A randomized trial. Am J Sports Med, 44(3):664–671.
5. Raeissadat SA, et al. (2019). Effectiveness of PRP in hip osteoarthritis. J Pain Res, 12:1655–1660.
6. Di Sante L, et al. (2021). Role of PRP in non-surgical management of hip OA. BMC Musculoskelet Disord, 22(1):991.
7. Mautner K, et al. (2015). Proposed classification for PRP use in orthopaedics. PM&R, 7(4 Suppl):S53–S59.
8. RegenOMedix. (2024). PRP Therapy. Available at: https://regenomedix.com/prp-therapy